Core Insights - Minerva Neurosciences, Inc. is hosting a virtual KOL event on February 3, 2026, to discuss the challenges of treating negative symptoms of schizophrenia and the upcoming Phase 3 trial of roluperidone [1][2] Company Overview - Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly targeting negative symptoms of schizophrenia with its product candidate roluperidone [9] Industry Context - Current antipsychotics do not adequately address negative symptoms of schizophrenia, which affects 50% to 60% of individuals with the disorder, highlighting an unmet medical need [2][8] - The FDA has recognized the lack of approved treatments specifically for negative symptoms and held a public meeting in August 2024 to discuss optimal clinical trial approaches [2][8] Expert Contributions - Gregory Strauss, PhD, and Brian Kirkpatrick, MD, MSPH, will provide insights during the KOL event, focusing on the patient burden of negative symptoms and the regulatory challenges in assessing these symptoms [1][4][5]

Core Insights - Minerva Neurosciences, Inc. has appointed Dr. Inderjit Kaul to its board of directors, who will also serve as a consultant for the clinical development of roluperidone [1][3] - The company successfully raised up to $200 million in a private placement to fund a Phase 3 trial for roluperidone, aimed at treating negative symptoms in schizophrenia [2] Company Developments - Dr. Kaul brings extensive experience in drug development, particularly in schizophrenia, having previously overseen the late-stage clinical development of Cobenfy at Bristol Myers Squibb [3] - The company plans to enhance its board with members experienced in schizophrenia clinical trials to support the Phase 3 trial of roluperidone [2] Clinical Context - Negative symptoms of schizophrenia, which include blunted affect and anhedonia, are a significant unmet medical need, with no FDA-approved treatments currently available for these symptoms [4][6] - Approximately 50% to 60% of individuals with schizophrenia experience primary negative symptoms, which do not respond to existing antipsychotic medications [6]

Core Insights - Minerva Neurosciences, Inc. has appointed Dr. Inderjit Kaul to its board of directors, who will also serve as a consultant for the clinical development of roluperidone [1][3] - The company successfully raised up to $200 million in a private placement to fund a confirmatory Phase 3 trial for roluperidone, aimed at treating negative symptoms in schizophrenia [2] Company Developments - Dr. Kaul brings extensive experience in drug development, particularly in neurology and schizophrenia, which will be beneficial for the upcoming Phase 3 trial of roluperidone [3] - The company plans to enhance its board with members experienced in schizophrenia clinical trials to support the clinical operations for roluperidone [2] Clinical Context - Negative symptoms of schizophrenia, such as blunted affect and anhedonia, are significant unmet needs, with no FDA-approved treatments currently available for these symptoms [4][6] - Approximately 50% to 60% of individuals with schizophrenia experience primary negative symptoms, which do not respond to existing antipsychotic treatments [6]